Self-Assembling Peptides for Prion Disease Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for transmissible spongiform encephalopathies and amyloid-producing neurodegenerative diseases, such as prion diseases, are ineffective, with no clinically effective chemical agents able to halt or reverse the diseases, and existing therapies primarily focus on immunomodulation or genetic manipulation, lacking targeted molecular interventions.
Innovation Solution
Development of self-assembling peptides, specifically a 16-mer RADA peptide that forms beta-sheet nanofibers, which binds to prion protein, delaying its conversion and accumulation, thereby inhibiting disease progression and promoting clearance of amyloid deposits, and can be used as both a therapeutic agent and diagnostic tool.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemical agents are used to treat prion diseases, then disease progression is targeted, but no clinically effective treatment is achieved
Solution Approach 1:
The patent uses synthetic peptides as intermediary molecules that bind to prion proteins and prevent their conversion to the pathological form. These peptides act as mediators between the therapeutic goal and the molecular mechanism, offering a novel approach that overcomes the limitations of conventional chemical agents by specifically targeting the protein-protein interaction involved in prion disease pathogenesis
2Reliability
If PrPc gene is ablated to prevent disease, then disease transmission is blocked, but genetic manipulation complexity increases
Solution Approach 1:
The patent extracts and isolates the critical functional element (the peptide sequence) that mediates prion prevention, separating it from the complex genetic manipulation approach. By using synthetic peptides instead of genetic ablation, the solution maintains disease prevention efficacy while eliminating the need for complex transgenic animal models or gene therapy procedures
3Reliability
If synthetic peptides are designed to inhibit protein mis-folding, then molecular conversion is blocked, but peptide design complexity increases
Solution Approach 1:
The patent systematically varies peptide parameters (amino acid sequence, length, charge, hydrophobicity) to optimize binding affinity and specificity for prion proteins. By changing these physical-chemical parameters, the invention achieves effective molecular conversion inhibition while establishing a rational design framework that reduces the complexity of peptide development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RADA peptide significantly extends animal survival, delays clinical symptoms, and facilitates the degradation and clearance of amyloid deposits, offering a novel molecular approach to impede prion transmission and disease progression, while also serving as a diagnostic and immunogenic tool.
Implementation Method 1
self-assembling peptides, specifically a 16-mer RADA peptide that forms beta-sheet nanofibers
Implementation Method 2
forms a hydrated scaffold of beta-sheet nanofibers
Implementation Method 3
physiochemical interaction of PrPsc with RADA results in a molecular complex
Implementation Method 4
this interaction can be competitively inhibited with Congo red
Data Source
AI summary
Self assembling peptides in combination with infectious and non-infectious proteins as inhibitors and diagnostic tools in transmissible spongiform encephalopathies and amyloid producing neuorodegenerative diseases are described herein.